PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
David J PropperFangfei GaoMark P SaundersDebashis SarkerJohn A HartleyVictoria J SpanswickHelen L LoweLouise D HackettTony T NgPaul R BarberGregory E WeitsmanSarah PearceLaura WhiteAndre LopesSharon L ForsythDaniel HochhauserPublished in: British journal of cancer (2022)
ClinicalTrials.gov number: NCT01862003.